Recent Publications

2024

Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2

Sharkey C, Long X, Al-Faouri R, Strand D, Olumi AF, Wang Z.

J Pathol. 2024 Apr 12. doi: 10.1002/path.6283. Epub ahead of print. PMID: 38606616.

The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016

Desmond C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim SP, Aghdam N, Olumi AF, Gershman B.

Prostate Cancer Prostatic Dis. 2024 Mar 30. doi: 10.1038/s41391-024-00822-2. Epub ahead of print. PMID: 38555410.

Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy

Schaufler C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B.

Prostate Cancer Prostatic Dis. 2024 Mar;27(1):81-88. doi: 10.1038/s41391-022-00619-1. Epub 2022 Nov 25. PMID: 36434164.

Practical Use of Self-Adjusted Nitrous Oxide During Transrectal Prostate Biopsy: A Double-Blind Randomized Controlled Trial

Escobar AJ, Krishna S, Flowers KM, Abello A, Gershman B, Wagner AA, Chang P, Korets R, Mistretta CJ, Schreiber KL, Olumi AF, Rayala HJ.

J Urol. 2024 Feb;211(2):214-222. doi: 10.1097/JU.0000000000003789. Epub 2023 Nov 20. PMID: 37984067.

2023

Effect of TNF-a Inhibitor Therapy on Growth of the Prostate Gland

Al-Faouri R, Sharkey C, Gershman B, Tsai LL, Wang Z, Olumi AF.

European Focus. 2023 Oct; doiL10.1016/j.euf.2023.10.015. Article in pre-print.

Conditional survival following radical cystectomy for urothelial carcinoma of the bladder

Moreno MF, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B.

Urol Oncol. 2023 Oct;41(10):432.e11-432.e20. doi: 10.1016/j.urolonc.2023.06.004. Epub 2023 Jul 26. PMID: 37500322.

Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection.

Morton E, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim SP, Bellmunt J, Kaplan I, Olumi AF, Gershman B.

Urol Oncol. 2023 May;41(5):255.e7-255.e14. doi: 10.1016/j.urolonc.2022.11.003. Epub 2022 Dec 2.

PMID: 36470805

Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer.

Estevez A, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Bellmunt J, Olumi AF, Rayala H, Gershman B.

Urol Oncol. 2023 May;41(5):255.e15-255.e21. doi: 10.1016/j.urolonc.2022.11.005. Epub 2022 Nov 28.

PMID: 36456453

Comparative Effectiveness of Magnetic Resonance Imaging-Ultrasound Fusion Versus In-bore Magnetic Resonance Imaging-targeted Prostate Biopsy.

Ramos F, Korets R, Fleishman A, Kaul S, Johnson M, Wei JL, Olumi AF, Tsai LL, Gershman B.

Urology. 2023 Jan;171:164-171. doi: 10.1016/j.urology.2022.09.016. Epub 2022 Oct 4.

PMID: 36206828

2022

Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy.

Schaufler C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B.

Prostate Cancer Prostatic Dis. 2022 Nov 25. doi: 10.1038/s41391-022-00619-1. Online ahead of print.

PMID: 36434164

5-Alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care.

Vaselkiv JB, Ceraolo C, Wilson KM, Pernar CH, Rencsok EM, Stopsack KH, Grob ST, Plym A, Giovannucci EL, Olumi AF, Kibel AS, Preston MA, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1460-1465. doi: 10.1158/1055-9965.EPI-21-1234.

PMID: 35255119 

Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.

Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim SP, Korets R, Chang P, Wagner A, Olumi AF, Gershman B.

Urol Oncol. 2022 Jun;40(6):272.e1-272.e9. doi: 10.1016/j.urolonc.2021.12.015. Epub 2022 Jan 17.

PMID: 35058142 

Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder.

Bharadwaj M, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B.

Urol Oncol. 2022 Jun;40(6):274.e15-274.e23. doi: 10.1016/j.urolonc.2022.02.002. Epub 2022 Mar 17.

PMID: 35307291

Zonal growth pattern of the prostate is affected by age and body mass index.

Sharkey C, Long X, Wang Z, Al-Faouri R, Gershman B, Tsai LL, Olumi AF.

J Urol. 2022 Apr;207(4):876-884. doi: 10.1097/JU.0000000000002332. Epub 2021 Dec 2.

PMID: 34854747

Single black men have the worst prognosis with localized prostate cancer.

Liu S, Wang Z, Long X, Fleishman A, Huang X, Wu Q, Gershman B, Olumi AF.

Can J Urol. 2022 Feb;29(1):10992-11002. PMID: 35150221.

2021

Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial.

Reitblat C, Fleishman A, Kaplan IA, Stensland KD, D’Amico AV, Olumi AF, Wagner AA, Chang PK, Kim SP, Korets R, Gershman B.

Urol Oncol. 2021 Apr 29:S1078-1439(21)00127-7. doi: 10.1016/j.urolonc.2021.03.017. Online ahead of print.

Advancing bladder preservation: Biomarkers, decision-making, and therapy.

McConkey D, Best CJM, Gumminger JA, Olumi AF.

Urol Oncol. 2021 Apr;39(4):199-200. doi: 10.1016/j.urolonc.2020.11.028. Epub 2021 Jan 22.

Sirt1 coordinates with ERα to regulate autophagy and adiposity.

Tao Z, Shi L, Parke J, Zheng L, Gu W, Dong XC, Liu D, Wang Z, Olumi AF, Cheng, Z.

Cell Death Discov. 2021 Mar 15;7(1):53. doi: 10.1038/s41420-021-00438-8.

Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men with Clinically Node-negative (cN0) Penile Cancer.

Unadkat P, Fleishman A, Olumi AF, Wagner A, Chang P, Kim SP, Korets R, Gershman B.

Urology. 2021 Feb 24:S0090-4295(21)00196-5. doi: 10.1016/j.urology.2021.02.019. Online ahead of print.

2020

Long-term Oncologic Impact of Positive Anterior and Posterior Surgical Margins After Radical Prostatectomy.

Wu, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Olumi AF, Dahl DM, Blute ML, Wu CL.

Am J Clin Oncol. 2020 Dec 1;43(12):872-879. doi: 10.1097/COC.0000000000000765.

The role of lymphadenectomy in patients with advanced renal cell carcinoma.

Unadkat P, Olumi AF, Gershman B.

Urol Clin North Am. 2020 Aug; 47(3):371-377. doi: 10.1016/j.ucl.2020.04.001. Epub 2020 Jun 7.

Epigenetic modulations and lineage plasticity in advanced prostate cancer.

Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, Huang K, Massari F, Lu X, Cimadamore A, Lopez-Beltran A, Cheng L.

Ann Oncol. 2020 Apr;31(4):470-479. doi: 10.1016/j.annonc.2020.02.002. Epub 2020 Feb 13.

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, Thomas D, Salari K, Wang Z, Romanel A, Te A, Lee R, Chughtai B, Olumi AF, Mosquera JM, Demichelis F, Elemento O, Rubin MA, Sboner A, Barbieri CE.

Nat Commun. 2020 Apr 24;11(1):1987. doi: 10.1038/s41467-020-15913-6. PMID: 32332823

High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5 Alpha-Reductase Inhibitors for Benign Prostatic Hyperplasia.

Zhang H, Frendl D, Wang Z, Olumi AF.

J Urol. 2020 Mar 13:101097 [Epub ahead of print] PMID:32167867

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.

Wang Z, Deng T, Long X, Lin X, Wu S, Wang H, Ge R, Zhang Z, Wu CL, Taplin ME, Olumi AF.

PLoS One. 2020 Mar 5;15(3):e0229754. doi: 10.1371/journal.pone.0229754. eCollection 2020. PMID: 32134978 

Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland.

Xue B, Wu S, Sharkey C, Tabatabaei S, Wu CL, Tao Z, Cheng Z, Strand D, Olumi AF, Wang Z.

Prostate Cancer Prostatic Dis. 2020 Feb 6. doi: 10.1038/s41391-020-0208-4. [Epub ahead of print] PMID: 32029929

2019

Impact of biopsy perineural invasion on the outcomes of patients who underwent radical prostatectomy: a systematic review and meta-analysis.

Wu S, Lin X, Lin SX, Lu M, Deng T, Wang Z, Olumi AF, Dahl DM, Wang D, Blute ML, Wu CL.

Scand J Urol. 2019 Oct;53(5):287-294. doi: 10.1080/21681805.2019.1643913. Epub 2019 Aug 10. PMID: 31401922

Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy.

Wu S, Lin SX, Lu M, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL.

Int Urol Nephrol. 2019 Sep;51(9):1527-1535. doi: 10.1007/s11255-019-02181-7. Epub 2019 Jun 10. PMID: 31183659

Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

Burns RB, Olumi AF, Owens DK, Smetana GW.

Ann Intern Med. 2019 Jun 4;170(11):770-778. doi: 10.7326/M19-1072. PMID: 31158876

2018

Prostate cancer in transgender women.

Ingham MD, Lee RJ, MacDermed D, Olumi AF.

Urol Oncol. 2018 Dec;36(12):518-525. doi: 10.1016/j.urolonc.2018.09.011. Epub 2018 Oct 12. Review. PMID: 30322726

Impact of Multifocality and Multilocation of Positive Surgical Margin After Radical Prostatectomy on Predicting Oncological Outcome.

Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL.

Clin Genitourin Cancer. 2019 Feb;17(1):e44-e52. doi: 10.1016/j.clgc.2018.08.007. Epub 2018 Aug 30. PMID: 30287224

BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions.

Yun H, Bedolla R, Horning A, Li R, Chiang HC, Huang TH, Reddick R, Olumi AF, Ghosh R, Kumar AP.

Int J Mol Sci. 2018 Jul 20;19(7). pii: E2104. doi: 10.3390/ijms19072104. PMID: 30036938 

Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue.

Vandergrift LA, Decelle EA, Kurth J, Wu S, Fuss TL, DeFeo EM, Halpern EF, Taupitz M, McDougal WS, Olumi AF, Wu CL, Cheng LL.

Sci Rep. 2018 Mar 26;8(1):4997. doi: 10.1038/s41598-018-23177-w. PMID: 29581441 

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.

Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H.

Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7. PMID: 29511347 

Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease? 

Wang Z, Olumi AF. 

Am J Physiol Renal Physiol. 2018 Mar 1;314(3):F407-F411. doi: 0.1152/ajprenal.00443.2017. PMID: 29117997

Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.

Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y, Zhu X, Olumi AF, Zhong WD, Wu CL.

Cancer Biol Ther. 2018 Mar 4;19(3):175-180. doi: 10.1080/15384047.2017.1414762. PMID: 29303414

Estradiol signaling mediates gender difference in visceral adiposity via autophagy.

Tao Z, Zheng LD, Smith C, Luo J, Robinson A, Almeida FA, Wang Z, Olumi AF, Liu D, Cheng Z.

Cell Death Dis. 2018 Feb 22;9(3):309. doi: 10.1038/s41419-018-0372-9. PMID: 29472585

2017

Androgenic to Estrogenic Switch in Human Adult Prostate Gland is regulated by Epigenetic Silencing of Steroid 5-α Reductase 2

Wang Z, Hu L, Salari K, Bechis S, Ge R, Wu S, Rassoulian C, Pham J, Wu CL, Tabatabaei S, Strand D, Olumi AF. J Pathol. 2017 Dec;243(4):457-467. doi: 10.1002/path.4985.

Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.

Frendl DM, Olumi AF.

Cancer. 2017 May 23. doi: 10.1002/cncr.30779.

PMID: 28542736

Metformin inhibits the proliferation of benign prostatic epithelial cells.

Wang Z, Xiao X, Ge R, Li J, Johnson CW, Rassoulian C, Olumi AF.

PLoS One. 2017 Mar 2;12(3):e0173335. doi: 10.1371/journal.pone.0173335.

PMID: 28253329

2015

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Wang Z, et al.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-304. doi: 10.1016/j.semcancer.2015.09.007. Review.

PMID: 26590477

Broad targeting of angiogenesis for cancer prevention and therapy.

Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD.

Semin Cancer Biol. 2015 Dec;35 Suppl:S224-43. doi: 10.1016/j.semcancer.2015.01.001. Epub 2015 Jan 16. Review.

PMID: 25600295

Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.

Ge R, Wang Z, Wu S, Zhuo Y, Otsetov AG, Cai C, Zhong W, Wu CL, Olumi AF.

Oncotarget. 2015 Oct 6;6(30):28973-87. doi: 10.18632/oncotarget.5023.

PMID: 26359363  

Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF.

J Urol. 2015 Oct;194(4):1031-7. doi: 10.1016/j.juro.2015.04.079. Epub 2015 Apr 25.

PMID: 25916673  

Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma.

Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong WD, Olumi A, Young RH, Wu CL.

Hum Pathol. 2015 Jun;46(6):820-6. doi: 10.1016/j.humpath.2015.02.013. Epub 2015 Mar 11.

PMID: 25827535  

Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.

Yun H, Xie J, Olumi AF, Ghosh R, Kumar AP.

Oncotarget. 2015 May 10;6(13):11600-13.

PMID: 25816367  

DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.

Ge R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, Wu CL, Tabatabaei S, Olumi AF.

Am J Pathol. 2015 Mar;185(3):870-82. doi: 10.1016/j.ajpath.2014.11.020. Epub 2015 Feb 17.

PMID: 25700986

SATB1 overexpression regulates the development and progression in bladder cancer through EMT.

Wan F, Cheng C, Wang Z, Xiao X, Zeng H, Xing S, Chen X, Wang J, Li S, Zhang Y, Xiang W, Zhu Z, Johnson C, Zhu Z.

PLoS One. 2015 Feb 23;10(2):e0117518. doi: 10.1371/journal.pone.0117518. eCollection 2015.

PMID: 25706386

2014

Metformin use and prostate cancer risk.

Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT.

Eur Urol. 2014 Dec;66(6):1012-20. doi: 10.1016/j.eururo.2014.04.027. Epub 2014 May 22.

PMID: 24857538  

Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases.

Rodríguez D, Preston MA, Barrisford GW, Olumi AF, Feldman AS.

Urol Oncol. 2014 Oct;32(7):958-65. doi: 10.1016/j.urolonc.2014.01.025. Epub 2014 Jul 11.

PMID: 25027684

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.

Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF.

JAMA Intern Med. 2014 Aug;174(8):1301-7. doi: 10.1001/jamainternmed.2014.1600.

PMID: 24887392

Personalized medicine for the management of benign prostatic hyperplasia.

Bechis SK, Otsetov AG, Ge R, Olumi AF.

J Urol. 2014 Jul;192(1):16-23. doi: 10.1016/j.juro.2014.01.114. Epub 2014 Feb 25. Review.

PMID: 24582540  

Prognostic significance of indeterminate lung nodules in renal cell carcinoma.

Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD.

Urol Oncol. 2014 Apr;32(3):355-61. doi: 10.1016/j.urolonc.2013.09.001. Epub 2014 Jan 4.

PMID: 24397994  

Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.

Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA.

J Oncol Pract. 2014 Mar;10(2):107-12. doi: 10.1200/JOP.2013.000902. Epub 2014 Jan 7.

PMID: 24399853

Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.

Hong J, Yuan Y, Wang J, Liao Y, Zou R, Zhu C, Li B, Liang Y, Huang P, Wang Z, Lin W, Zeng Y, Dai JL, Chung RT.

Cancer Res. 2014 Mar 15;74(6):1845-56. doi: 10.1158/0008-5472.CAN-13-2104. Epub 2014 Jan 29.

PMID: 24477596

Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation.

Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q, Olumi AF, Zhang X.

Mol Cancer Res. 2014 Feb;12(2):217-27. doi: 10.1158/1541-7786.MCR-13-0441. Epub 2013 Dec 2.

PMID: 24296757

Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46.

Olumi AF.

Urol Oncol. 2014 Feb;32(2):210-1. doi: 10.1016/j.urolonc.2013.08.020.

PMID: 24445292

Commentary on "randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients." Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R, Department of Nutritional Sciences, University of Toronto, Ontario, Canada.: J Clin Endocrinol Metab 2013;98(4):1498-507 [Epub 2013 Mar 5].

Olumi AF.

Urol Oncol. 2014 Feb;32(2):210. doi: 10.1016/j.urolonc.2013.08.021.

PMID: 24445291

Commentary on "integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer." Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T, Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.: Cancer Cell 2013;23(2):159-70.

Olumi AF.

Urol Oncol. 2014 Feb;32(2):212. doi: 10.1016/j.urolonc.2013.08.018.

PMID: 24445294

Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA et. al.

Olumi AF.

Urol Oncol. 2014 Feb;32(2):211. doi: 10.1016/j.urolonc.2013.08.019.

PMID: 24445293

Commentary on "ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients." Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z, Division of Hematology and Oncology, Boston Children's Hospital, Boston, MA, USA.: Genes Dev 2013;27(6):683-98.

Olumi AF.

Urol Oncol. 2014 Feb;32(2):213. doi: 10.1016/j.urolonc.2013.08.016.

PMID: 24445296

Commentary on "age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis." De Angulo A, Faris R, Cavazos D, Jolly C, Daniel B, DeGraffenried L, Department of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas, Austin, TX, USA.: Prostate 2013;73(8):855-64 [Epub 2013 Mar 26].

Olumi AF.

Urol Oncol. 2014 Feb;32(2):212-3. doi: 10.1016/j.urolonc.2013.08.017.

PMID: 24445295

Quantization and diagnosis of Shanghuo (Heatiness) in Chinese medicine using a diagnostic scoring scheme and salivary biochemical parameters.

Liu S, Huang Z, Wu Q, Huang Z, Wu L, Yan W, Chang DL, Yang Z, Wang Z.

Chin Med. 2014 Jan 4;9(1):2. doi: 10.1186/1749-8546-9-2.

PMID: 24386887

Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes.

Rodríguez D, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi AF.

Urol Oncol. 2014 Jan;32(1):52.e19-25. doi: 10.1016/j.urolonc.2013.08.009. Epub 2013 Nov 13.

PMID: 24239475

2013

Models of care and NCCN guideline adherence in very-low-risk prostate cancer.

Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.

J Natl Compr Canc Netw. 2013 Nov;11(11):1364-72.